Medtech fundings in March 2015

Fundings for medical technologies in March 2015 totaled $542 million, led by the $57 million funding of EndoChoice, Inc.

Below are the top fundings for the month.

Company, fundingProduct/technology
EndoChoice, Inc., has raised $57 million in a round of funding, according to the companyEndoscopes and other instrumentation in gastroenterology
Apollo Endosurgery, Inc., has closed a $50 million secured term loan according to the companyMinimally invasive endoscopic surgical products for bariatric and gastrointestinal procedures
Semma Therapeutics has raised $44 million in a Series A round of funding according to the companyCell therapy for type I diabetes
Svelte Medical Systems, Inc., has raised $38.01 million of a planned $48.74 million round of funding according to a regulatory filingDrug eluting and other coronary stents
Auxogyn, Inc., has raised $34.32 million of a planned $40 million round of funding according to a regulatory filingDiagnostic and other technologies focused on women’s reproductive health
SteadyMed Therapeutics, Inc., has raised $39.95 million in its IPO according to press reportsPatch-pump drug delivery technology
Hansen Medical, Inc., has raised $35 million in a round of funding according to a regulatory filingIntravascular robotics

For the complete list of medtech fundings in March 2015, see link.

For a historical list of the individual fundings in medtech, by month, since 2009, see link.

Established to emerging, commodity to advanced in wound management

Wound management is about as diverse a market as there can be in medtech. Wounds can be acute or chronic, surgically created or arising from trauma or disease, treated with technology as simple as a piece of gauze or as complex as a hyperbaric oxygen chamber or negative pressure would therapy technology.  The manufacturers range from producers of largely commodity-like dressings to devices to equipment to growth factors and other biotech products.

Simultaneously, the nature of patient populations, clinical practices, market development, economics and technology adoption vary widely around the world, resulting in considerable variation in the sales of traditional products all the way up through the most advanced products in wound management.

As an example, below are illustrations of the 2011 to 2020 forecast for the range of wound management products in the U.S. and a different set of markets, the Rest of Asia/Pacific (excluding Japan and Korea); predominantly China, India and Australia.

The distribution of product sales in wound management, on a relative basis, is very different in the U.S. than in the Rest of Asia/Pacific due in large part to the tendency for advanced technologies to be first introduced in well developed markets, like the U.S., Europe, Japan and others and later migrated to the “emerging” markets. T

The U.S. graph illustrates the decreasing/increasing share of each technology’s sales relative to all others.

Screen Shot 2014-05-20 at 3.23.43 PM

Source: MedMarket Diligence, LLC; Report #S249

For the Rest of Asia/Pacific Market, a different picture emerges, with interesting variations per product segment.



Screen Shot 2014-05-20 at 3.23.58 PM

Source: MedMarket Diligence, LLC; Report #S249

However, to put the relative differences into a meaningful context, one has to look at the absolute sales in the different markets. And, to show the very real, stark difference between the U.S. and Rest of Asia/Pacific markets for wound management products, we have plotted both on the same scale, with the max given for both as $12,000 million in sales.



Screen Shot 2014-05-20 at 3.24.16 PM

Source: MedMarket Diligence, LLC; Report #S249

Screen Shot 2014-05-20 at 3.29.56 PM

Source: MedMarket Diligence, LLC; Report #S249